Nalls Sherbakoff Group’s AbbVie ABBV Stock Holding History

Nalls Sherbakoff Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$75.9K	Sell	332 -243	-42%	-$55.4K	0.05%	165
2025 Q3	$133K	Hold	575	–	–	0.09%	125
2025 Q2	$107K	Hold	575	–	–	0.08%	137
2025 Q1	$120K	Buy	+575	New	+$112K	0.1%	113
2023 Q4	$105K	Hold	675	–	–	0.09%	113
2023 Q3	$101K	Hold	675	–	–	0.1%	111
2023 Q2	$93.1K	Hold	675	–	–	0.09%	115
2023 Q1	$107K	Buy	+675	New	+$103K	0.11%	111
2018 Q4	$83K	Buy	+895	New	+$78.7K	0.13%	90

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nalls Sherbakoff Group's ABBV Position: Q4 2025 in Review

Nalls Sherbakoff Group reduced its AbbVie (ABBV) stake by 42% in Q4 2025, selling an estimated $55.4K and leaving 332 shares worth $75.9K. The position accounts for 0.05% of the portfolio, ranked #165.

Nalls Sherbakoff Group first reported a position in ABBV in Q4 2018 and has held it in 9 quarters since. The position peaked at $133K in Q3 2025. 4,146 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Nalls Sherbakoff Group held 332 shares of AbbVie worth $75.9K as of Q4 2025.
Nalls Sherbakoff Group sold 243 AbbVie shares in Q4 2025, an estimated $55.4K.
AbbVie made up 0.05% of Nalls Sherbakoff Group's portfolio in Q4 2025, its #165 holding.
Nalls Sherbakoff Group first reported a position in AbbVie in Q4 2018 and has held it in 9 quarters since.
Nalls Sherbakoff Group's AbbVie position peaked at $133K in Q3 2025.
4,146 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Nalls Sherbakoff Group's 13F filing for Q4 2025, filed 12 Mar 2026.